Revlimid revenue phasing uncertainty
Management could not provide precise timing of Revlimid revenue decline, which may impact quarterly US revenue and margins.
high · analyst_questionCipla Ltd — Q1 FY26
Cipla reported Q1 FY26 revenue of INR 6,957 crore (+4% YoY) with EBITDA margin of 25.6% (flat YoY) and PAT of INR 1,298 crore (+10.2% YoY).
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Slower India branded prescription growth
India branded business grew only ~3% (ex-consumer), impacted by slow respiratory/acute market and sales force realignment; recovery may take longer.
medium · management_commentaryIndore facility reinspection risk
Indore facility is due for US FDA reinspection within the next year; any adverse outcome could disrupt US supplies.
high · analyst_questionGLP-1 market competition and execution
Management acknowledged GLP-1 market will be crowded; Cipla's strategy is still evolving and may face challenges in capturing share.
medium · analyst_question